Skip to main content
SpringerLink
Log in

Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective hematopoiesis with a high risk of transformation to acute myeloid leukemia (AML). miRNAs function as tumor suppressors and oncogenes in various cancers and regulate the differentiation potential of hematopoietic stem and progenitor cells (HSPCs). It has been suggested that miRNAs may play an important role in progression of MDS. We analyzed bone marrow samples collected from MDS patients according to different risk stratification indicated by the International Prognostic Scoring System (IPSS). We demonstrated that miR-196b-5p was up-regulated in intermediate II and higher groups, and in secondary AML (s-AML) patients in particular (P < 0.01) compared with healthy controls, suggesting that the higher expression levels are associated with increased risk of the development of MDS. We observed changes in proliferation and apoptosis in MDS-L cells following transfection with miR-196-5p mimics or inhibitors. After up-regulating the expression of miR-196b-5p, proliferation of MDS-L cells was up-regulated, whereas apoptosis was down-regulated (P < 0.05). In contrast, down-regulation of miR-196b-5p expression decreased cell proliferation and increased apoptosis (P < 0.05). We concluded that over-expression of miR-196b-5p may be closely associated with the risk of transformation to leukemia in MDS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014;49(4):216–27.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Issa JP. Epigenetic changes in the myelodysplastic syndromes. Hematol Oncol Clin N Am. 2010;24(2):317–30.

    Article  Google Scholar 

  3. Schemenau J, Balsus S, Anlauf M, Reinecke P, Braunstein S, Blum S, et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol. 2015;95(3):181–9.

    Article  PubMed  Google Scholar 

  4. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol. 2001;73(4):416–28.

    Article  CAS  PubMed  Google Scholar 

  5. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–13.

    Article  CAS  PubMed  Google Scholar 

  6. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120(10):2076–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromess. Lancet. 2014;383(9936):2239–52.

    Article  PubMed  Google Scholar 

  8. Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol. 2008;87(10):777–95.

    Article  PubMed  Google Scholar 

  9. Bally C, Thepot S, Quesnel B, Quesnel B, Vey N, Deryfus F, et al. Azacitidine in the treatment of therapy related myelodysplastic syndromes and acute myeloid leukemia (t-MDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Res. 2013;37(6):637–40.

    Article  CAS  Google Scholar 

  10. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.

    Article  CAS  PubMed  Google Scholar 

  11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  12. Hatfield S, Ruohola-Baker H. MicroRNA and stem cell function. Cell Tissue Res. 2008;331(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  13. Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006;12(5):913–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) method. Methods. 2001;25(4):402–8.

    Article  CAS  PubMed  Google Scholar 

  15. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011; 17(9):3029–38.

  16. Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods. 1993;157(1–2):223–40.

    Google Scholar 

  17. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA. 2010;107(32):14229–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Djuranovic S, Nahvi A, Green R. A parsimonius model for gene regulation by miRNAs. Science. 2011;331(6017):550–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Iwasaki H, Akashi K. Hematopoietic development pathways: on cellular basis. Oncogene. 2007;26(47):6687–96.

    Article  CAS  PubMed  Google Scholar 

  20. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell. 2012;10(2):120–36.

    Article  CAS  PubMed  Google Scholar 

  21. O’Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA. 2010;107(32):14235–40.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011;153(1):24–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, et al. Myeloid cell differentiation arrest by miR -125b-1 in myelodysplastic syndromes and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205(11):2499–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hussein K, Theophile K, Büsche G, Schlegelberger B, Göhring G, Kreipe H, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leukemia Res. 2010;34(9):1169–74.

    Article  CAS  Google Scholar 

  26. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma. 2009;50(11):1854–9.

    Article  CAS  PubMed  Google Scholar 

  27. McGlinn E, Yekta S, Mansfield JH, Soutscjel J, Bartel DP, Tabin CJ. In ovo application of antagomiRs indicates a role for miR-196 in patterning the chick axial skeleton through Hox gene regulation. Pro Natl Acad Sci USA. 2009; 106(44):18610–5.

  28. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117(4):1121–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Danen-van AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, Trka J, et al. Differrentially expressed microRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukimia. Pediatr Blood Cancer. 2012;58(5):715–21.

    Article  Google Scholar 

  30. Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemia. Blood Cells Mol Dis. 2010;44(3):191–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009;113(14):3314–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Merritt WM, Bar⁃Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010;70(7):2571–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23(23):2700–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fu CM, Chen ZX, Liu DD, Zhang J, Pan JL, Liang JY. Clonal origin and evolution of myelodysplastic syndromes analyzed by dysplastic morphology and fluorescence in situ hybridization. Int J Hematol. 2015;101(1):58–66.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Hematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China

      Jing Wen, Ying Huang, Xupai Zhang, Peng Cheng, Donghong Deng, Zhigang Peng, Jun Luo, Weihua Zhao, Yongrong Lai & Zhenfang Liu

    2. Hematology Department, First People’s Hospital of Nanning, Nanning, 530022, Guangxi, China

      Hongying Li

    Authors
    1. Jing Wen
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ying Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Hongying Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xupai Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Peng Cheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Donghong Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Zhigang Peng
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Jun Luo
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Weihua Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Yongrong Lai
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Zhenfang Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Zhenfang Liu.

    Ethics declarations

    Funding

    This work has been supported by a grant from the National Natural Science Foundation of China (Nos. 81560028 and 81160072), Natural Science Foundation of Guangxi Province (No. 2010GXNSFB 013064).

    Conflict of interest

    The authors have no conflict of interest to disclose.

    Additional information

    J. Wen and Y. Huang contributed equally to this work.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wen, J., Huang, Y., Li, H. et al. Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome. Int J Hematol 105, 777–783 (2017). https://doi.org/10.1007/s12185-017-2201-9

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12185-017-2201-9

    Keywords

    Search

    Navigation